Future Oriented Project

Studies on new drugs for health

Investment in the field of diseases that require innovative solutions with high quality.
Bayer HealthCare occupies 67 percent of all the costs of research and development in the Bayer Group, and most of this investment is in the development of phase 3 clinical trials that are currently in progress.
As a result of this research and development, Bayer’s pharmaceutical pipeline is robust.
Research and development in the Pharmaceuticals segment is strategically aligned to the conditions in its markets. In drug discovery we focus on four growth areas: diagnostic imaging, cardiology, oncology, and women’s healthcare. The respective research activities and capacities are concentrated at three sites in Berlin and Wuppertal, Germany, and Berkeley, California. Work at the Berlin and Wuppertal sites focuses on identifying molecular targets in order to develop and optimize lead substances. Research is also carried out at these sites in the fields of drug metabolism, pharmacokinetics, toxicology and clinical pharmacology. Berkeley is an important global research and development center for protein-based active ingredients and is home to the biotechnological production facility for Kogenate®.

Crop Studies

Equipped with high innovative capabilities: Bayer CropScience
is expected to launch six new products related to the protection
of crops by 2012, and this is expected to lead to sales at 100 million Euros. Bayer CropScience is investing intensely in the improvement of seeds and plants in addition to the existing field of crop protection. The main goal of this study is the achievement of a qualitative improvement of crops including cotton, canola and rice.

Studies for a comfortable life

From megatrends to business, these studies encompass examination of:
• an airplane powered by solar energy finishes its historic flight,
• robots wear clothes made by Bayer,
• malaria is prevented by a mosquito net that contains insecticide